McKesson Corporation

Proton Capital Enters Into Agreement to Purchase PharmaChoice Canada Branded Pharmacy In Saskatoon For Proposed Qualifying Transaction

Retrieved on: 
Thursday, February 22, 2024

The Share Purchase Agreement provides that Proton will purchase 75% of the issued and outstanding shares of the Target Pharmacy.

Key Points: 
  • The Share Purchase Agreement provides that Proton will purchase 75% of the issued and outstanding shares of the Target Pharmacy.
  • The Qualifying Transaction will not constitute a Non-Arm’s Length Qualifying Transaction (as such term is ‎defined in the policies of the TSXV).
  • The parties to the Qualifying Transaction are at arm’s length and therefore the approval of the shareholders of ‎Proton in respect of the Qualifying Transaction will not be required.
  • The Prospectus will contain important detailed information about the Corporation, the Qualifying ‎Transaction and the proposed Offering.

50/50 WOMEN ON BOARDS KICKS OFF SECOND ANNUAL 50 WOMEN TO WATCH FOR BOARDS CAMPAIGN

Retrieved on: 
Friday, March 8, 2024

LOS ANGELES, March 8, 2024 /PRNewswire/ -- 50/50 Women on Boards™ (50/50WOB), the leading global nonprofit education and advocacy organization driving the movement toward gender balance and diversity on corporate boards, kicks-off  its second annual 50 Women to Watch for Boards campaign on International Women's Day.

Key Points: 
  • "We are steadfast in our mission of amplifying women in the pipeline for corporate board leadership," stated Heather Spilsbury, CEO of 50/50 Women on Boards.
  • According to 50/50 Women on Boards' 2023 Q4 Gender Diversity Index Research, 43 percent of Russell 3000 Index companies still have two or fewer women on their boards.
  • The 50 Women to Watch for Boards campaign addresses this disparity by providing corporations, nominating and corporate governance committee chairs, and recruiters access to a curated list of highly accomplished women ready to serve on public company boards.
  • To be eligible for the 50 Women to Watch for Boards list, candidates must be based in North America.

Vaniam Group™ Hires Carol Scholz as Executive Vice President of Client Solutions

Retrieved on: 
Monday, March 4, 2024

CHICAGO, March 4, 2024 /PRNewswire/ -- Vaniam Group™ today announced the hiring of Carol Scholz as Executive Vice President of Client Solutions. In this role, Ms. Scholz will lead overall client strategy and solutions, while guiding the collaboration and growth of the Client Services department, the Scientific Communications department, and Curio Science™, Vaniam Group's industry leading platform for scientific exchange and insights gathering. She will serve as a member of the Executive Committee and report directly to Vaniam Group's President, Jennifer Buffington Herzog.

Key Points: 
  • CHICAGO, March 4, 2024 /PRNewswire/ -- Vaniam Group™ today announced the hiring of Carol Scholz as Executive Vice President of Client Solutions.
  • In this role, Ms. Scholz will lead overall client strategy and solutions, while guiding the collaboration and growth of the Client Services department, the Scientific Communications department, and Curio Science™ , Vaniam Group's industry leading platform for scientific exchange and insights gathering.
  • She will serve as a member of the Executive Committee and report directly to Vaniam Group's President, Jennifer Buffington Herzog.
  • "Carol brings a passion for delivering strategic solutions and operational excellence, always anchored in the science and centered around the needs of the patient," said Ms. Herzog.

Astellas Names Michael Petroutsas as Head of US Commercial

Retrieved on: 
Thursday, February 22, 2024

NORTHBROOK, Ill., Feb. 22, 2024 /PRNewswire/ -- Today, Astellas Pharma Inc. Chief Commercial Officer Claus Zieler has named Michael Petroutsas as Head, United States Commercial, leading the Astellas Pharma US Inc. organization.

Key Points: 
  • NORTHBROOK, Ill., Feb. 22, 2024 /PRNewswire/ -- Today, Astellas Pharma Inc. Chief Commercial Officer Claus Zieler has named Michael Petroutsas as Head, United States Commercial, leading the Astellas Pharma US Inc. organization.
  • Petroutsas will succeed Mark Reisenauer, who is leaving Astellas at the end of March.
  • "With more than 25 years of experience in the pharmaceutical industry, Mike has effectively led extensive global commercial, strategic, and operational teams.
  • Prior to Astellas, Petroutsas served as Senior Vice President, US Specialty and Oncology Business, at GSK.

Health Data Movers Welcomes Robert Coman as Sales Director

Retrieved on: 
Friday, February 16, 2024

NEW YORK, Feb. 16, 2024 /PRNewswire-PRWeb/ -- Health Data Movers (HDM), a "Best in KLAS" healthcare technology services firm, announced today that Robert "Bob" Coman is joining the Client Services team as Sales Director.

Key Points: 
  • Health Data Movers welcomes Robert "Bob" Coman to the Client Services team as Sales Director.
  • NEW YORK, Feb. 16, 2024 /PRNewswire-PRWeb/ -- Health Data Movers (HDM), a "Best in KLAS" healthcare technology services firm, announced today that Robert "Bob" Coman is joining the Client Services team as Sales Director.
  • Darin Ryder, VP of Client Services, shared, "We are thrilled to have Bob join Health Data Movers as our new Sales Director and leader of the Account Management team.
  • "As a Sales Director in the dynamic field of healthcare IT, my vision aligns seamlessly with Health Data Movers' ethos: to be healthcare's most respected technology services firm.

Immuron achieves record Travelan® sales

Retrieved on: 
Tuesday, February 13, 2024

MELBOURNE, Australia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record sales (unaudited net sales) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.

Key Points: 
  • MELBOURNE, Australia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record sales (unaudited net sales) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.
  • Sales of Travelan® increased to AUD $2.1 million YTD Jan 2024 compared to AUD $0.3 million YTD Jan 2023.
  • Flavio Palumbo, Chief Commercial Officer said, “We are excited by the strong sales results on Travelan®.
  • Immuron’s investment to drive awareness of the Travelan® brand has seen strong sales results in Australia over the summer peak travel period.

McKesson’s Practice Insights Designated as a 2024 Qualified Clinical Data Registry by Centers for Medicare & Medicaid Services

Retrieved on: 
Thursday, February 8, 2024

For the eighth consecutive year, McKesson has received approval from the Centers for Medicare & Medicaid Services (CMS) to participate in the Merit-based Incentive Payment System (MIPS) as a Qualified Clinical Data Registry (QCDR).

Key Points: 
  • For the eighth consecutive year, McKesson has received approval from the Centers for Medicare & Medicaid Services (CMS) to participate in the Merit-based Incentive Payment System (MIPS) as a Qualified Clinical Data Registry (QCDR).
  • The designation enables healthcare practices and providers utilizing iKnowMed℠ electronic health record (EHR) to efficiently submit data directly to CMS without engaging a separate registry vendor, streamlining data submission and minimizing administrative burden.
  • As a CMS-approved QCDR, Practice Insights ℠, a performance analytics tool powered by Ontada ®, can collect and report clinical data on behalf of clinicians for standard MIPS measures.
  • It also continues to provide meaningful insights to improve care while simultaneously easing the burden of participating in CMS regulatory programs.

McKesson Corporation Reports Fiscal 2024 Third Quarter Results and Raises Full Year Guidance

Retrieved on: 
Wednesday, February 7, 2024

McKesson Corporation (NYSE: MCK) has released its fiscal 2024 third quarter financial results.

Key Points: 
  • McKesson Corporation (NYSE: MCK) has released its fiscal 2024 third quarter financial results.
  • Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results .
  • As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, February 7th at 4:30 PM ET to review its financial results.
  • The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company’s earnings press release, financial tables, and slide presentation.

BrillDog Announces Formation of Expert Board to Drive Strategic Growth

Retrieved on: 
Wednesday, February 7, 2024

NEW FREEDOM, Pa., Feb. 7, 2024 /PRNewswire-PRWeb/ -- BrillDog, a leading supply chain tech platform, proudly unveils its' newly assembled Board of Directors, comprised of seasoned professionals with diverse expertise in supply chain, business, technology, finance, and fundraising. The esteemed board has been strategically curated to provide invaluable oversight, guidance, and consultation to propel the company's growth and success. The Board is led by the company's founder, industry vet Sam Polakoff who has spent the better part of 40 years bringing supply chain process and technology innovation to the SMB market.

Key Points: 
  • The esteemed board has been strategically curated to provide invaluable oversight, guidance, and consultation to propel the company's growth and success.
  • "We're excited to welcome a talented, diverse Board of Directors to BrillDog.
  • Their expertise will drive innovation and success in the dynamic supply chain tech landscape, shaping strategic decisions for growth and ROI."
  • The Board has been formed to play a crucial role in shaping BrillDog's future by offering expert insights and strategic direction in key areas.

Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer

Retrieved on: 
Tuesday, February 6, 2024

NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into a distribution agreement with Cardinal Health for its HemeScreen molecular assay products.

Key Points: 
  • NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into a distribution agreement with Cardinal Health for its HemeScreen molecular assay products.
  • Under the agreement, Cardinal Health will market and distribute Precipio’s HemeScreen portfolio of molecular assays to its customer base, which comprises primarily the acute healthcare systems (hospital networks), as well as reference laboratories and physician owned laboratories.
  • “The addition of this agreement with Cardinal Health, and alongside distribution agreements Precipio has with Fisher Healthcare and McKesson, strengthens our distribution network and positions us for growth in 2024”, said Ilan Danieli, Precipio’s CEO.
  • “Cardinal Health is a formidable player in the market, and we are excited to work with them to deliver value to their customers, and to the patients they serve”.